TriMixDC-MEL Plus Ipilimumab Active in Pretreated Advanced Melanoma

Share this content:
Autologous monocyte-derived dendritic cells electroporated with synthetic mRNA (TriMixDC-MEL) was tolerable in pretreated advanced melanoma.
Autologous monocyte-derived dendritic cells electroporated with synthetic mRNA (TriMixDC-MEL) was tolerable in pretreated advanced melanoma.

Autologous monocyte-derived dendritic cells (DCs) electroporated with synthetic mRNA (TriMixDC-MEL) in combination with ipilimumab was tolerable and resulted in highly durable responses in patients with pretreated advanced melanoma, a study published in the Journal of Clinical Oncology has shown.1

TriMixDC-MEL have previously been shown to be immunogenic and have antitumor activity in patients with pretreated advanced melanoma. Because ipilimumab, a cytotoxic T-lymphocyte-associated protein 4 antibody, improves overall survival in patients with advanced melanoma, researchers sought to investigate the combination of both in the pretreated population.

 

For the phase 2 study, researchers enrolled 39 patients. All participants received TriMixDC-MEL 4 × 106 cells administered intradermally and 20 × 106 cells administered intravenously, plus ipilimumab 10 mg/kg every 3 weeks for 4 doses. Patients who remained progression-free then received maintenance therapy every 12 weeks.

Results showed that the 6-month disease control rate was 51% (95% CI, 36 - 67) and the overall tumor response rate was 38%.

Eight patients achieved complete responses and 7 had partial responses. Of those, 7 complete responses and 1 partial response are ongoing after a median follow-up of 36 months.

In regard to safety, the most common treatment-emergent adverse events were local dendritic cell injection site reactions, transient post-dendritic cell infusion chills and flu-like symptoms, dermatitis, hypophysitis, diarrhea/colitis, and hepatitis.

RELATED: BRAF V600E Expression Is a Novel Prognostic Marker in Primary Melanoma

A total of 36% of patients experienced grade 3 or 4 immune-related adverse events, but no grade 5 events were reported.

Reference

  1. Wilgenhof S, Corthals J, Heirman C, et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma [published online ahead of print February 29, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.63.4121.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters